The NEJM has published SERENA-6 data ahead of ASCO #ASCO25 plenary. Cami joins other SERDS (elacestrant, imlunestrant, vepdegestrant) with activity in ESR1mut BC Key questions to think about ahead of session: nejm.org/doi/full/10.10…

At #ASCO25 Dana-Farber’s Dr. Erica Mayer presented results of the TRADE study showing that an abemaciclib dose escalation strategy allowed a greater number of pts (70.8%) to reach & maintain higher dose levels of the CDK 4/6 inhibitor. Dana-Farber’s Breast Oncology Center

Amazing Women in Oncology OncLive.com event! Eleonora Teplinsky, MD Stephanie A. Haddad, DO Reshma Mahtani #ASCO25

Check out my summary of our poster at #ASCO25 in collaboration with Foundation Medicine ! 🔍ERBB2 amplification predicts benefit from T-DXd and T-DM1 beyond clinical HER2 IHC status; technologies that better quantify HER2 dependence are needed to guide selection btw HER2 directed

DB-09 will change the way we treat HER2+ metastatic breast cancer… but how?! Had a fun interview with OncLive.com about the many open questions and opportunities for tailoring treatment for these patients Dana-Farber’s Breast Oncology Center

With ASCO25 wrapping up, I wanted to acknowledge the impact of a person that— between leading Dana-Farber’s Breast Oncology Center, caring for patients, mentoring countless physicians, parenting 2 teenagers — also led 2 trials that will impact lives for thousands of pts globally. Congrats Sara Tolaney!

So many important, practice-changing presentations at #ASCO25, but the best part was seeing the work of my incredible Dana-Farber co-fellows 🌟🌟🌟 Sara Khosrowjerdi Char, MD Sarah Waliany, MD, MS Tess O'Meara, MD, MHS Ashley Odai-Afotey, MD

Woah

This is wild! Engineering E. coli bacteria to turn plastic waste into paracetamol (Tylenol) Nature Chemistry nature.com/articles/s4155… nature.com/articles/s4155…

T-DXd may be a new 1L option for HER2+ metastatic #breastcancer, but which other pts could benefit? Ongoing trials are studying T-DXd in combo with endocrine and targeted therapies as well as in HER2 null disease and early-stage/residual disease. Thanks OncLive.com for hosting!

More fun with OncLive.com Komal Jhaveri Kevin Kalinsky, MD, MS, FASCO discussing controversial topics in recent breast cancer trials. Hearing clinical insights from these thoughtful, dedicated mentors & friends is a day well spent!!! Glamor shot by Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 📸

In an interview, Tess O'Meara, MD, MHS highlighted: ⭐️ Key efficacy and safety data from DESTINY-Breast09 ⭐️ The potential implications of these findings regarding T-DXd in the first-line setting ⭐️ Ongoing research focused on refining the use of T-DXd in combination strategies

Sticking with hormonal therapy can be challenging, but there are ways to make it easier. Here's what to consider before stopping or refusing treatment, including tips to help manage side effects: bit.ly/4dW7aPl #HormonalTherapy #BreastCancer #BreastCancerSurvivor

Check out this recent paper on #InflammatoryBreastCancer, it examines the clinicogenomic characterization of #IBC. 👉pubmed.ncbi.nlm.nih.gov/40378057/ @npriedig Brittany Bychkovsky, MD jennifer bellon Tari King MD Eric Winer, MD Lynette Sholl Sara Tolaney Nancy Lin, MD Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 Romualdo Barroso, MD PhD

T-DXd Retreatment After ILD (Pooled analysis – 9 trials, 2145 pts) 🔹️23% of pts with G1 ILD were retreated 🔹️ILD recurrence in 33% (all G1–2, no G5) 🔹️20% discontinued due to ILD2 🔹️75% of steroid-treated pts recovered 💥 Retreatment appears feasible with proper

Pearls for talking to patients: 1) AI for 5 years is the goal, more has modest benefits. 2) 5 additional years reduces recurrence risk by 3-4%, most of these are new breast events 3) reduces distant recurrence by 2% (5 more years) 4) no OS benefit

How do different breast cancer treatments perform immediately after T-DXd? In our latest #JNCI paper, we analyzed data from ~800 pts with MBC in Flatiron, finding promising rwPFS with several regimens, yet some degree cross-resistance between T-DXd and SG. academic.oup.com/jnci/advance-a…

Platelets can sequester cfDNA! Via Science Magazine science.org/doi/10.1126/sc…

The eponymous "Nancy Lin Rule" holds again for treatment of CNS metastases. The best drug 'outside' the CNS will also be the best drug in the CNS. And the corollary is: the best way to identify new CNS treatments is to have potent new drugs that work outside the CNS.

New review in npj Breast Cancer on #AntibodyDrugConjugates for treating early-stage #BreastCancer discusses current use and anticipated evolutions. Read it here: 🔓pubmed.ncbi.nlm.nih.gov/40739147/ ✍️#PoojaPatel Antonio Giordano, MD PhD Ilana Schlam Sara Tolaney Paolo Tarantino #ADCs